Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients - PubMed (original) (raw)

Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients

W E Van Nostrand et al. Proc Natl Acad Sci U S A. 1992.

Abstract

The amyloid beta-protein is deposited in senile plaques and the cerebrovasculature in Alzheimer disease (AD). Since it is derived from proteolytic processing of its parent protein, the amyloid beta-protein precursor (APP), we investigated whether levels of the secreted forms of APP are altered in cerebrospinal fluid (CSF) of AD patients. Quantitative immunoblotting studies with the anti-APP monoclonal antibody P2-1 revealed that probable AD patients had markedly lower CSF APP levels than did demented non-Alzheimer-type patients and healthy control subjects. Using antibody P2-1 in an enzyme-linked immunosorbent assay, we measured CSF levels of APP in a larger population consisting of 13 patients diagnosed with probable AD, 18 patients diagnosed with dementia (non-Alzheimer type), and 16 nondemented, healthy controls. Mean CSF levels of APP were approximately 3.5-fold lower in the live patients diagnosed with probable AD compared to the demented non-Alzheimer-type controls or the nondemented, healthy individuals. These findings suggest that abnormal metabolism of APP is reflected in the extracellular fluids of the central nervous system and that CSF levels of soluble APP provide a useful biochemical marker to assist in the clinical diagnosis of AD.

PubMed Disclaimer

Similar articles

• Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity.
  Hock C, Golombowski S, Müller-Spahn F, Naser W, Beyreuther K, Mönning U, Schenk D, Vigo-Pelfrey C, Bush AM, Moir R, Tanzi RE, Growdon JH, Nitsch RM. Hock C, et al. Eur Neurol. 1998;39(2):111-8. doi: 10.1159/000007917. Eur Neurol. 1998. PMID: 9520072 Clinical Trial.
• Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid.
  Portelius E, Brinkmalm G, Tran A, Andreasson U, Zetterberg H, Westman-Brinkmalm A, Blennow K, Ohrfelt A. Portelius E, et al. Exp Neurol. 2010 Jun;223(2):351-8. doi: 10.1016/j.expneurol.2009.06.011. Epub 2009 Jun 25. Exp Neurol. 2010. PMID: 19559702
• Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls.
  Peskind ER, Leverenz J, Farlow MR, Ito RK, Provow SA, Siegel RS, Cleveland M, Morgan CH, Pandian MR, Corbin S, Nochlin D, Schellenberg GD, Raskind MA, Wagner SL. Peskind ER, et al. Alzheimer Dis Assoc Disord. 1997 Dec;11(4):201-6. Alzheimer Dis Assoc Disord. 1997. PMID: 9437437
• The beta amyloid protein precursor: mRNAs, membrane-associated forms, and soluble derivatives.
  Palmert MR, Podlisny MB, Golde TE, Cohen ML, Kovacs DM, Tanzi RE, Gusella JF, Whitehouse PJ, Witker DS, Oltersdorf T, et al. Palmert MR, et al. Prog Clin Biol Res. 1989;317:971-84. Prog Clin Biol Res. 1989. PMID: 2513588 Review.
• Alzheimer's disease.
  De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. De-Paula VJ, et al. Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Subcell Biochem. 2012. PMID: 23225010 Review.

Cited by

• CSF tau and β-amyloid as biomarkers for mild cognitive impairment.
  Hampel H, Blennow K. Hampel H, et al. Dialogues Clin Neurosci. 2004 Dec;6(4):379-90. doi: 10.31887/DCNS.2004.6.4/hhampel. Dialogues Clin Neurosci. 2004. PMID: 22034251 Free PMC article.
• Transthyretin sequesters amyloid beta protein and prevents amyloid formation.
  Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK, et al. Schwarzman AL, et al. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8368-72. doi: 10.1073/pnas.91.18.8368. Proc Natl Acad Sci U S A. 1994. PMID: 8078889 Free PMC article.
• β-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin.
  Wong BX, Tsatsanis A, Lim LQ, Adlard PA, Bush AI, Duce JA. Wong BX, et al. PLoS One. 2014 Dec 2;9(12):e114174. doi: 10.1371/journal.pone.0114174. eCollection 2014. PLoS One. 2014. PMID: 25464026 Free PMC article.
• Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.
  Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K. Hampel H, et al. Exp Neurol. 2010 Jun;223(2):334-46. doi: 10.1016/j.expneurol.2009.09.024. Epub 2009 Oct 6. Exp Neurol. 2010. PMID: 19815015 Free PMC article. Review.
• Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tau.
  Ray B, Reyes PF, Lahiri DK. Ray B, et al. J Psychiatr Res. 2011 Apr;45(4):539-47. doi: 10.1016/j.jpsychires.2010.07.011. Epub 2010 Sep 9. J Psychiatr Res. 2011. PMID: 20828718 Free PMC article.

References

1. 1. Science. 1990 Apr 27;248(4954):492-5 - PubMed
2. 1. Nature. 1988 Feb 11;331(6156):528-30 - PubMed
3. 1. J Biol Chem. 1990 Mar 15;265(8):4492-7 - PubMed
4. 1. Biochem Biophys Res Commun. 1990 Feb 14;166(3):1453-9 - PubMed
5. 1. Science. 1990 Jun 1;248(4959):1122-4 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information